Absci (ABSI) Change in Receivables (2024 - 2025)

Absci (ABSI) posted Change in Receivables of -$1.0 million for Q4 2025, down 433.33% sequentially from $300000.0 in Q3 2025, and up 33.33% YoY from -$750000.0 in Q4 2024.

Absci (ABSI) Change in Receivables (2024 - 2025) Analysis & Trends

Absci has reported Change in Receivables for 2 years, with the latest figure at -$1.0 million in Q4 2025.

  • Quarterly Change in Receivables rose 33.33% year-over-year to -$1.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$1.4 million (down 207.12% YoY) and the FY2024 annual result came in at -$2.2 million, down 436.19% from the prior year.
  • Change in Receivables eased to -$1.0 million in Q4 2025 per ABSI's latest filing, from $300000.0 in the prior quarter.
  • Over five years, Change in Receivables peaked at $1.4 million in Q3 2024 and troughed at -$2.1 million in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 140.20 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 838.50 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 117.58 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -483,662.49
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 31.60 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 37.16 Mn
10 Absci 1.58 Bn 1.37 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -1.00 Mn
Dec 31, 2025 -1.00 Mn
Sep 30, 2025 300,000.00
Sep 30, 2025 300,000.00
Jun 30, 2025 -684,000.00
Jun 30, 2025 -684,000.00
Mar 31, 2025 1.38 Mn
Mar 31, 2025 1.38 Mn
Dec 31, 2024 -1.50 Mn
Dec 31, 2024 -1.50 Mn
Sep 30, 2024 1.41 Mn
Sep 30, 2024 1.41 Mn
Jun 30, 2024 3,000.00
Jun 30, 2024 3,000.00
Mar 31, 2024 -2.15 Mn
Mar 31, 2024 -2.15 Mn